These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10615347)

  • 1. Active surveillance of adverse events associated with naltrexone in New South Wales.
    Thackway SV; Ward PL; Taylor LK
    Med J Aust; 1999 Nov; 171(9):499-500. PubMed ID: 10615347
    [No Abstract]   [Full Text] [Related]  

  • 2. Risks associated with the inappropriate use of naltrexone in the treatment of opioid dependence.
    Latt NC
    Med J Aust; 1999 Nov; 171(9):500-1. PubMed ID: 10615348
    [No Abstract]   [Full Text] [Related]  

  • 3. [Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
    Poser W; Ehrenreich H
    Internist (Berl); 1996 Oct; 37(10):1061-7; discussion 1067. PubMed ID: 9019453
    [No Abstract]   [Full Text] [Related]  

  • 4. Is naltrexone a cure for heroin dependence?
    Hall WD; Wodak A
    Med J Aust; 1999 Jul; 171(1):9-10. PubMed ID: 10451663
    [No Abstract]   [Full Text] [Related]  

  • 5. Methods of detoxification and their role in treating patients with opioid dependence.
    O'Connor PG
    JAMA; 2005 Aug; 294(8):961-3. PubMed ID: 16118388
    [No Abstract]   [Full Text] [Related]  

  • 6. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts.
    Miotto K; McCann MJ; Rawson RA; Frosch D; Ling W
    Drug Alcohol Depend; 1997 Apr; 45(1-2):131-4. PubMed ID: 9179515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone in the treatment of opioid-dependent pregnant women: common ground.
    Jones HE; Chisolm MS; Jansson LM; Terplan M
    Addiction; 2013 Feb; 108(2):255-6. PubMed ID: 23331881
    [No Abstract]   [Full Text] [Related]  

  • 8. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy.
    Degenhardt L; Gibson A; Mattick RP; Hall W
    Drug Alcohol Rev; 2008 Jan; 27(1):1-3. PubMed ID: 18034375
    [No Abstract]   [Full Text] [Related]  

  • 9. Unplanned admissions to two Sydney public hospitals after naltrexone implants.
    Lloyd-Jones DM
    Med J Aust; 2008 Oct; 189(8):468-9; author reply 470-1. PubMed ID: 18928445
    [No Abstract]   [Full Text] [Related]  

  • 10. Naltrexone in the treatment of opioid dependence.
    George S; Ekhtiari H
    Br J Hosp Med (Lond); 2010 Oct; 71(10):568-70. PubMed ID: 21085073
    [No Abstract]   [Full Text] [Related]  

  • 11. Unplanned admissions to two Sydney public hospitals after naltrexone implants.
    Kozminsky MP
    Med J Aust; 2008 Oct; 189(8):469-70; author reply 470-1. PubMed ID: 19031547
    [No Abstract]   [Full Text] [Related]  

  • 12. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose.
    Ritter AJ
    Aust N Z J Psychiatry; 2002 Apr; 36(2):224-8. PubMed ID: 11982544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.
    Gonzalez JP; Brogden RN
    Drugs; 1988 Mar; 35(3):192-213. PubMed ID: 2836152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
    Krupitsky EM; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):49-56. PubMed ID: 25591636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
    Jhugroo A; Ellayah D; Norman A; Hulse G
    J Psychopharmacol; 2014 Aug; 28(8):800-3. PubMed ID: 24695742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to Degenhardt et al.: 'depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy'.
    Brewer C
    Drug Alcohol Rev; 2008 Jul; 27(4):447-8; author reply 448-9. PubMed ID: 18584398
    [No Abstract]   [Full Text] [Related]  

  • 19. [The development of coma after the use of naltrexone in a patient with opioid addiction].
    Sivolap IuP; Savchenkov VA; Mishnaevskiĭ AL; Iakovchuk AM; Rasulov MM; Kaludzherovich LV; Parfenov DA; Mustafin KhKh
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(8):55-7. PubMed ID: 10983373
    [No Abstract]   [Full Text] [Related]  

  • 20. Haight-Ashbury free clinics' drug detoxification protocols--Part 2: Opioid blockade.
    Galloway G; Hayner G
    J Psychoactive Drugs; 1993; 25(3):251-2. PubMed ID: 8258763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.